FARON.HE
Strong SellSinkerFaron Pharmaceuticals Oy · Healthcare · Finland · $97M · Avg Vol: $349K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT FARON PHARMACEUTICALS OY
Read
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for hard-to-treat cancers. The company's competitive moat is centered on its proprietary antibody platform, specifically its lead candidate bexmarilimab, which targets myeloid cell receptors to overcome immunosuppression. It is a high-risk, high-reward biotechnology player dependent on clinical trial outcomes and strategic partnerships.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS (EUR) | -0.32 | -0.15 | -0.16 | -0.27 | -0.22 | — | -0.12 | -0.11 | -0.13 | — |
| Shares | — | 202.9M | 202.9M | 113.8M | 124.4M | -38.7% | — | — | — | — |
| Debt | — | 13.3M | 13.1M | 12.1M | 24.7M | 23.0% | 18.0M | — | — | — |
| Equity | — | -11.5M | -15.2M | -9.8M | -18.5M | — | — | — | — | — |
| Op CF | — | -23.0M | -23.8M | -22.3M | -17.9M | — | -20.3M | — | — | — |
| Inv CF | — | -0.4M | -0.1M | 0.1M | -20.0K | — | — | — | — | — |
| Fin CF | — | 23.5M | 24.0M | 24.8M | 20.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FARON.HE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FARON.HE | Faron Pharmaceuticals Oy(you) | $97M | 5 | Strong Sell |
| HRTIS.HE | Herantis Pharma Oyj | $51M | 5 | Strong Sell |
| NANOFH.HE | Nanoform Finland Oyj | $86M | 31 | Sell |
| AIFORIA.HE | Aiforia Technologies Oyj | $74M | 3 | Strong Sell |
| HEALTH.HE | Nightingale Health Oyj | $65M | 13 | Strong Sell |
| OPTOMED.HE | Optomed Oyj | $59M | 16 | Strong Sell |
| NXTMH.HE | Nexstim Plc | $79M | 27 | Sell |
| MODU.HE | Modulight Oyj | $51M | 32 | Sell |
| REG1V.HE | Revenio Group Oyj | $435M | 44 | Hold |
| ORIOLA.HE | Oriola Oyj | $191M | 67 | Buy |
Peer medians: ROE -14.3% · P/E 19.5x · Gross margin 65.9%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.